Search research articles
Contact Us
Filters
Showing results (1-10 of 29) with videos related to
Page
of 3
Sort By:
Recent Patents on CNS Drug Discovery
|
January 28, 2012
Cannabinoids: novel medicines for the treatment of Huntington's disease
Onintza Sagredo, M Ruth Pazos, Sara Valdeolivas, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
February 15, 2020
Possible therapeutic applications of cannabis in the neuropsychopharmacology field
Javier Fernández-Ruiz, Ismael Galve-Roperh, Onintza Sagredo, et al.
Current Topics in Behavioral Neurosciences
|
July 24, 2025
Ageing, Neurodegeneration and the Endocannabinoid System
Javier Fernández-Ruiz, Onintza Sagredo, María Gómez-Ruiz, et al.
ACS Chemical Neuroscience
|
August 4, 2012
Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors
Sara Valdeolivas, Valentina Satta, Roger G Pertwee, et al.
Neuropharmacology
|
June 8, 2023
Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1a
Cristina Alonso, Valentina Satta, Inés Hernández-Fisac, et al.
The European Journal of Neuroscience
|
August 4, 2007
Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors
Onintza Sagredo, José A Ramos, Alessandra Decio, et al.
Neuropharmacology
|
December 7, 2021
Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome
Cristina Alonso, Valentina Satta, Paula Díez-Gutiérrez, et al.
International Journal of Molecular Sciences
|
March 24, 2017
Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease
Sara Valdeolivas, Onintza Sagredo, Mercedes Delgado, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
September 26, 2014
Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice
Sara Valdeolivas, Carmen Navarrete, Irene Cantarero, et al.
Mini Reviews in Medicinal Chemistry
|
July 20, 2005
Therapeutic potential of the endocannabinoid system in the brain
José Antonio Ramos, Sara González, Onintza Sagredo, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 29) with videos related to
Sort By:
Page
of 3
Recent Patents on CNS Drug Discovery
|
January 28, 2012
Cannabinoids: novel medicines for the treatment of Huntington's disease
Onintza Sagredo, M Ruth Pazos, Sara Valdeolivas, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
February 15, 2020
Possible therapeutic applications of cannabis in the neuropsychopharmacology field
Javier Fernández-Ruiz, Ismael Galve-Roperh, Onintza Sagredo, et al.
Current Topics in Behavioral Neurosciences
|
July 24, 2025
Ageing, Neurodegeneration and the Endocannabinoid System
Javier Fernández-Ruiz, Onintza Sagredo, María Gómez-Ruiz, et al.
ACS Chemical Neuroscience
|
August 4, 2012
Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors
Sara Valdeolivas, Valentina Satta, Roger G Pertwee, et al.
Neuropharmacology
|
June 8, 2023
Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1a
Cristina Alonso, Valentina Satta, Inés Hernández-Fisac, et al.
The European Journal of Neuroscience
|
August 4, 2007
Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors
Onintza Sagredo, José A Ramos, Alessandra Decio, et al.
Neuropharmacology
|
December 7, 2021
Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome
Cristina Alonso, Valentina Satta, Paula Díez-Gutiérrez, et al.
International Journal of Molecular Sciences
|
March 24, 2017
Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease
Sara Valdeolivas, Onintza Sagredo, Mercedes Delgado, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
September 26, 2014
Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice
Sara Valdeolivas, Carmen Navarrete, Irene Cantarero, et al.
Mini Reviews in Medicinal Chemistry
|
July 20, 2005
Therapeutic potential of the endocannabinoid system in the brain
José Antonio Ramos, Sara González, Onintza Sagredo, et al.
Page
of 3